SI2481409T1 - Nanodelci, ki zajemajo rapamicin in albumin kot sredstvo proti raku - Google Patents
Nanodelci, ki zajemajo rapamicin in albumin kot sredstvo proti rakuInfo
- Publication number
- SI2481409T1 SI2481409T1 SI200831982T SI200831982T SI2481409T1 SI 2481409 T1 SI2481409 T1 SI 2481409T1 SI 200831982 T SI200831982 T SI 200831982T SI 200831982 T SI200831982 T SI 200831982T SI 2481409 T1 SI2481409 T1 SI 2481409T1
- Authority
- SI
- Slovenia
- Prior art keywords
- rapamycin
- nanoparticle
- albumin
- anticancer agent
- anticancer
- Prior art date
Links
- 102000009027 Albumins Human genes 0.000 title 1
- 108010088751 Albumins Proteins 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 239000002105 nanoparticle Substances 0.000 title 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title 1
- 229960002930 sirolimus Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Molecular Biology (AREA)
- Radiology & Medical Imaging (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90578707P | 2007-03-07 | 2007-03-07 | |
| US90573407P | 2007-03-07 | 2007-03-07 | |
| US90575007P | 2007-03-07 | 2007-03-07 | |
| US90576707P | 2007-03-07 | 2007-03-07 | |
| US90566207P | 2007-03-07 | 2007-03-07 | |
| US90567207P | 2007-03-07 | 2007-03-07 | |
| US90566907P | 2007-03-07 | 2007-03-07 | |
| US90566307P | 2007-03-07 | 2007-03-07 | |
| US90573507P | 2007-03-07 | 2007-03-07 | |
| US92324807P | 2007-04-13 | 2007-04-13 | |
| US92345607P | 2007-04-13 | 2007-04-13 | |
| EP12152463.1A EP2481409B1 (en) | 2007-03-07 | 2008-03-07 | Nanoparticle comprising rapamycin and albumin as anticancer agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2481409T1 true SI2481409T1 (sl) | 2018-09-28 |
Family
ID=39562000
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200831982T SI2481409T1 (sl) | 2007-03-07 | 2008-03-07 | Nanodelci, ki zajemajo rapamicin in albumin kot sredstvo proti raku |
| SI200831985T SI2481402T1 (sl) | 2007-03-07 | 2008-03-07 | Nanodelci, ki zajemajo rapamicin in albumin, kot sredstvo proti raku |
| SI200831980T SI2131821T1 (sl) | 2007-03-07 | 2008-03-07 | Nanodelci, ki zajemajo rapamicin in albumin kot sredstvo proti raku |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200831985T SI2481402T1 (sl) | 2007-03-07 | 2008-03-07 | Nanodelci, ki zajemajo rapamicin in albumin, kot sredstvo proti raku |
| SI200831980T SI2131821T1 (sl) | 2007-03-07 | 2008-03-07 | Nanodelci, ki zajemajo rapamicin in albumin kot sredstvo proti raku |
Country Status (24)
Families Citing this family (122)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5439686A (en) * | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US20030199425A1 (en) * | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
| SI1585548T1 (sl) | 2002-12-09 | 2018-11-30 | Abraxis Bioscience, Llc | Sestave in metode odmerjanja farmakoloških sredstev |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| SI2301531T1 (sl) | 2005-02-18 | 2018-11-30 | Abraxis Bioscience, Llc | Kombinacije in načini dajanja terapevtskih sredstev in kombinacijska terapija |
| PL3311805T3 (pl) * | 2005-08-31 | 2020-07-27 | Abraxis Bioscience, Llc | Kompozycje zawierające słabo rozpuszczalne w wodzie środki farmaceutyczne i środki przeciwdrobnoustrojowe |
| LT2117520T (lt) | 2006-12-14 | 2018-12-10 | Abraxis Bioscience, Llc | Krūties vėžio terapija hormonų receptoriaus statuso pagrindu su nanodalelėmis, apimančiomis taksaną |
| MX380318B (es) * | 2007-03-07 | 2025-03-12 | Abraxis Bioscience Llc | Nanoparticula que comprende rapamicina y albumina como agente anticancer. |
| US20100166869A1 (en) * | 2007-05-03 | 2010-07-01 | Desai Neil P | Methods and compositions for treating pulmonary hypertension |
| AU2008260447B2 (en) * | 2007-06-01 | 2013-10-10 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
| US20100048914A1 (en) | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
| CA2721153C (en) * | 2008-04-10 | 2018-10-02 | Abraxis Bioscience, Llc | Compositions of hydrophobic taxane derivatives and uses thereof |
| WO2010005726A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences Inc. | Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same |
| EP2309990B2 (en) | 2008-06-16 | 2017-03-15 | Pfizer Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
| EP2309991B1 (en) | 2008-06-16 | 2019-03-06 | Pfizer Inc | Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same |
| CN102227221A (zh) * | 2008-11-28 | 2011-10-26 | 诺瓦提斯公司 | 包含hsp90抑制剂和mtor抑制剂的药物组合 |
| JP2012512175A (ja) | 2008-12-15 | 2012-05-31 | バインド バイオサイエンシズ インコーポレイテッド | 治療薬を徐放するための長時間循環性ナノ粒子 |
| BRPI1008745A2 (pt) | 2009-02-05 | 2019-09-17 | Tokai Pharmaceuticals Inc | pró-fármacos de inibidores esteroidais de cyp17/antiandrogênios |
| CN102612564B (zh) * | 2009-04-10 | 2015-08-26 | 齐海燕 | 新的抗衰老试剂及其鉴别方法 |
| KR20120044279A (ko) | 2009-04-15 | 2012-05-07 | 아브락시스 바이오사이언스, 엘엘씨 | 무-프리온 나노입자 조성물 및 방법 |
| EP2509634B1 (en) | 2009-12-11 | 2019-03-06 | Pfizer Inc | Stable formulations for lyophilizing therapeutic particles |
| WO2011084513A2 (en) | 2009-12-15 | 2011-07-14 | Bind Biosciences, Inc. | Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers |
| KR101267813B1 (ko) * | 2009-12-30 | 2013-06-04 | 주식회사 삼양바이오팜 | 향상된 수용해도를 갖는 라파마이신 함유 고분자나노입자 주사제형 조성물 및 그 제조방법, 및 방사선 요법과 병용하기 위한 항암 조성물 |
| GB2478556A (en) * | 2010-03-09 | 2011-09-14 | Myrovlytis Technology Ventures Ltd | A composition for use in the treatment of Birt-Hogg-Dubô sydrome |
| BR112012024349A2 (pt) | 2010-03-26 | 2016-05-24 | Abraxis Bioscience Llc | métodos de tratamento de carcinoma hepatocelular |
| CN105147613A (zh) | 2010-03-29 | 2015-12-16 | 阿布拉科斯生物科学有限公司 | 增强药物递送和治疗剂有效性的方法 |
| RU2016119999A (ru) | 2010-03-29 | 2018-11-08 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способы лечения онкологических заболеваний |
| WO2011133668A2 (en) * | 2010-04-20 | 2011-10-27 | President And Fellows Of Harvard College | Methods and compositions for the treatment of cancer |
| EP2575804A4 (en) | 2010-06-04 | 2013-10-23 | Abraxis Bioscience Llc | METHOD FOR THE TREATMENT OF PANCREASCRE |
| WO2012054564A2 (en) * | 2010-10-19 | 2012-04-26 | The Curators Of The University Of Missouri | Anti-vegf antibody/fragment conjugated gold nanoparticles, and fabrication and therapeutic methods |
| US8691777B2 (en) | 2011-01-27 | 2014-04-08 | Emory University | Combination therapy |
| WO2012149451A1 (en) * | 2011-04-28 | 2012-11-01 | Abraxis Bioscience, Llc | Intravascular delivery of nanoparticle compositions and uses thereof |
| CN104623666A (zh) | 2011-04-29 | 2015-05-20 | 西莱克塔生物科技公司 | 用于诱导调节性b细胞的致耐受性合成纳米载体 |
| EP2707030B1 (en) | 2011-05-09 | 2020-02-19 | Mayo Foundation For Medical Education And Research | Cancer treatments |
| RU2705998C2 (ru) | 2011-12-14 | 2019-11-13 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Применение полимерных эксципиентов для лиофилизации или заморозки частиц |
| WO2013148158A1 (en) * | 2012-03-30 | 2013-10-03 | President And Fellows Of Harvard College | Laser-actuated therapeutic nanoparticles |
| AU2013274101B2 (en) * | 2012-06-15 | 2017-09-07 | The Brigham And Women's Hospital, Inc. | Compositions for treating cancer and methods for making the same |
| JP2015526471A (ja) * | 2012-08-21 | 2015-09-10 | ジェネシス リサーチ インスティチュート | アントラサイクリン誘発性心毒性を治療または予防するための組成物および方法 |
| EA032943B1 (ru) | 2012-09-17 | 2019-08-30 | Пфайзер Инк. | Способ получения терапевтических наночастиц (варианты) и терапевтическая наночастица (варианты) |
| CA2885022A1 (en) * | 2012-09-17 | 2014-03-20 | Bind Therapeutics, Inc. | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same |
| WO2014055415A1 (en) | 2012-10-01 | 2014-04-10 | Mayo Foundation For Medical Education And Research | Cancer treatments |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| WO2014107384A1 (en) * | 2013-01-03 | 2014-07-10 | The Board Of Regents Of The University Of Texas System | Rapamycin analogs targeting proteasome function in the treatment of cancer |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| US10172789B2 (en) | 2013-01-24 | 2019-01-08 | Palvella Therapeutics Llc | Compositions for transdermal delivery of mTOR inhibitors |
| ES2804323T3 (es) | 2013-03-12 | 2021-02-05 | Abraxis Bioscience Llc | Procedimientos de tratamiento de cáncer de pulmón |
| CN105246468A (zh) * | 2013-03-14 | 2016-01-13 | 阿布拉科斯生物科学有限公司 | 治疗膀胱癌的方法 |
| SG11201507093WA (en) | 2013-03-14 | 2015-10-29 | Univ Maryland Baltimore Office Of Technology Transfer | Androgen receptor down-regulating agents and uses thereof |
| WO2014144405A1 (en) * | 2013-03-15 | 2014-09-18 | The Board Of Regents Of The University Of Texas System | Use of mtor inhibitors for prevention of neuroendocrine tumor development and growth |
| KR101329646B1 (ko) | 2013-05-02 | 2013-11-14 | 주식회사 지니스 | 표적지향증폭형 항암나노입자 및 이의 제조방법 |
| CA2910579C (en) * | 2013-05-03 | 2023-09-26 | Selecta Biosciences, Inc. | Dosing combinations for reducing undesired humoral immune responses |
| MX380164B (es) * | 2013-05-03 | 2025-03-12 | Selecta Biosciences Inc | Uso de una macromolécula terapéutica y una composición que comprende nanoportadores sintéticos que se unen a inmunosupresores para reducir la hipersensibilidad tipo i y tipo iv en un sujeto. |
| CA2920317A1 (en) | 2013-08-12 | 2015-02-19 | Tokai Pharmaceuticals, Inc. | Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies |
| PL3046584T3 (pl) | 2013-09-16 | 2017-11-30 | Astrazeneca Ab | Terapeutyczne polimeryczne nanocząstki i sposoby ich wytwarzania i stosowania |
| CN106061470A (zh) * | 2013-10-22 | 2016-10-26 | 北卡罗来纳大学查珀尔希尔分校 | 含有多种物质的聚合物纳米粒子及其方法 |
| AU2014373683B2 (en) | 2013-12-31 | 2020-05-07 | Rapamycin Holdings, Llc | Oral rapamycin nanoparticle preparations and use |
| HUP1400075A2 (hu) | 2014-02-14 | 2015-08-28 | Druggability Technologies Ip Holdco Jersey Ltd | Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói |
| HUE043964T2 (hu) | 2014-03-14 | 2019-09-30 | Pfizer | Terápiás szert tartalmazó terápiás nanorészecskék és eljárás ezek elõállítására és alkalmazására |
| AU2015274408A1 (en) | 2014-06-13 | 2017-01-12 | Mayo Foundation For Medical Education And Research | Treating lymphomas |
| EA201692502A1 (ru) | 2014-06-16 | 2017-09-29 | Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч | Лечение миелом |
| IL292574A (en) | 2014-09-07 | 2022-06-01 | Selecta Biosciences Inc | Methods and compositions for attenuating anti-viral transfer vector immune responses |
| US9446148B2 (en) | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| WO2016172069A1 (en) * | 2015-04-20 | 2016-10-27 | Washington State University | Methods of treating inflammation associated airway diseases and viral infections |
| US20160346221A1 (en) | 2015-06-01 | 2016-12-01 | Autotelic Llc | Phospholipid-coated therapeutic agent nanoparticles and related methods |
| JP6871919B2 (ja) | 2015-06-16 | 2021-05-19 | ナノファギックス エルエルシー | 薬物送達及びイメージング化学コンジュゲート、製剤及びその使用方法 |
| EA201890159A1 (ru) * | 2015-06-29 | 2018-11-30 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | СПОСОБЫ ЛЕЧЕНИЯ ГЕМАТОЛОГИЧЕСКОГО ЗЛОКАЧЕСТВЕННОГО НОВООБРАЗОВАНИЯ С ПОМОЩЬЮ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ |
| MX2017016519A (es) * | 2015-06-29 | 2018-08-16 | Abraxis Bioscience Llc | Biomarcadores para composiciones de nanoparticulas. |
| NZ738929A (en) * | 2015-06-29 | 2024-01-26 | Abraxis Bioscience Llc | Methods of treating solid tumors using nanoparticle mtor inhibitor combination therapy |
| AU2016285720C1 (en) | 2015-06-29 | 2022-02-03 | Abraxis Bioscience, Llc | Methods of treating epithelioid cell tumors |
| TW201707725A (zh) | 2015-08-18 | 2017-03-01 | 美國馬友醫藥教育研究基金會 | 載體－抗體組合物及其製造及使用方法 |
| CN114796130B (zh) * | 2015-08-18 | 2023-10-20 | 梅约医学教育与研究基金会 | 载体结合剂组合物及其制备和使用方法 |
| TW201713360A (en) | 2015-10-06 | 2017-04-16 | Mayo Foundation | Methods of treating cancer using compositions of antibodies and carrier proteins |
| US10765665B2 (en) | 2015-11-24 | 2020-09-08 | Melin Jeffrey | Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases |
| US20220280233A1 (en) * | 2015-12-23 | 2022-09-08 | Theromics, Inc. | Devices, methods, and compositions for thermal acceleration and drug delivery |
| WO2017120501A1 (en) | 2016-01-07 | 2017-07-13 | Mayo Foundation For Medical Education And Research | Methods of treating cancer with interferon |
| CA3013783A1 (en) | 2016-02-04 | 2017-08-10 | The Johns Hopkins University | Rapaglutins, novel inhibitors of glut and use thereof |
| CN108697701B (zh) | 2016-02-04 | 2021-10-26 | 约翰霍普金斯大学 | 平衡型核苷转运蛋白1的抑制剂Rapadocin及其用途 |
| CA3014531A1 (en) | 2016-02-12 | 2017-08-17 | Mayo Foundation For Medical Education And Research | Hematologic cancer treatments |
| WO2017143092A1 (en) | 2016-02-19 | 2017-08-24 | Nant Holdings Ip, Llc | Methods of immunogenic modulation |
| JP2019510085A (ja) * | 2016-03-08 | 2019-04-11 | ロス ガトス ファーマスーティカルズ， インク．Ｌｏｓ Ｇａｔｏｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 癌治療のためのナノ粒子ならびに方法および化合物 |
| US11878061B2 (en) | 2016-03-21 | 2024-01-23 | Mayo Foundation For Medical Education And Research | Methods for improving the therapeutic index for a chemotherapeutic drug |
| CA3018341A1 (en) | 2016-03-21 | 2017-09-28 | Mayo Foundation For Medical Education And Research | Methods for reducing toxicity of a chemotherapeutic drug |
| US10618969B2 (en) | 2016-04-06 | 2020-04-14 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| US10894960B2 (en) | 2016-08-30 | 2021-01-19 | Children's Hospital Medical Center | Compositions and methods for nucleic acid transfer |
| CN109843336A (zh) | 2016-09-01 | 2019-06-04 | 梅约医学教育与研究基金会 | 用于靶向t细胞癌症的方法和组合物 |
| KR102462041B1 (ko) | 2016-09-01 | 2022-11-02 | 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 | 암 치료용 담체－ｐｄ－ｌ１ 결합제 조성물 |
| JP7025412B2 (ja) | 2016-09-06 | 2022-02-24 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ | パクリタキセル－アルブミン－結合剤組成物並びに該組成物の使用及び製造方法 |
| CN109843924A (zh) | 2016-09-06 | 2019-06-04 | 梅约医学教育与研究基金会 | 治疗表达pd-l1的癌症的方法 |
| EP3509635A1 (en) | 2016-09-06 | 2019-07-17 | Vavotar Life Sciences LLC | Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins |
| WO2018064405A1 (en) * | 2016-09-28 | 2018-04-05 | Abraxis Bioscience, Llc | Methods of treating mitochondrial and metabolic disorders |
| IL302385B2 (en) | 2017-01-06 | 2024-06-01 | Palvella Therapeutics Inc | Non-aqueous preparations of mTOR inhibitors and methods of use |
| US11013731B2 (en) | 2017-01-06 | 2021-05-25 | Santen Pharmaceutical Co., Ltd. | Intratumoral administration of sirolimus for treatment of prostate cancer |
| WO2018169811A1 (en) | 2017-03-11 | 2018-09-20 | Selecta Biosciences, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
| US12411144B2 (en) | 2017-03-22 | 2025-09-09 | Children's Hospital Medical Center | Compositions and methods for treatment of lung function |
| US10806801B2 (en) | 2017-06-07 | 2020-10-20 | National Cheng Kung University | Pharmaceutical composition and methods for using the same |
| WO2019073371A1 (en) | 2017-10-11 | 2019-04-18 | Wockhardt Limited | PHARMACEUTICAL COMPOSITION COMPRISING ALBUMIN-LIPID HYBRID NANOPARTICLES |
| JP2021506839A (ja) * | 2017-12-19 | 2021-02-22 | アブラクシス バイオサイエンス， エルエルシー | ナノ粒子ｍＴＯＲ阻害剤併用治療を使用して結腸がんを処置する方法 |
| KR20210013542A (ko) * | 2017-12-21 | 2021-02-04 | 빈센트 더블유. 리 | 신생물을 치료하기 위한 조성물 및 방법 |
| JP7402806B2 (ja) * | 2018-02-23 | 2023-12-21 | バイオトロニック アクチェンゲゼルシャフト | ４０－ｏ－環状炭化水素エステル及び関連構造のための非経口製剤材料及び方法 |
| SG11202009145PA (en) * | 2018-03-20 | 2020-10-29 | Abraxis Bioscience Llc | Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin |
| JP7561628B2 (ja) | 2018-05-22 | 2024-10-04 | アブラクシス バイオサイエンス， エルエルシー | 肺高血圧症を処置するための方法および組成物 |
| EP3817743A4 (en) | 2018-07-02 | 2022-07-06 | Palvella Therapeutics, Inc. | ANHYDROUS COMPOSITIONS OF MTOR INHIBITORS AND METHODS OF USE |
| US20220054404A1 (en) * | 2019-03-19 | 2022-02-24 | Abraxis Bioscience, Llc | Subcutaneous administration of nanoparticles comprising an mtor inhibitor and albumin for treatment of diseases |
| EP3999153A4 (en) * | 2019-07-16 | 2023-08-16 | The Regents Of The University Of Michigan | Composite drug particles and uses thereof |
| WO2021086946A1 (en) * | 2019-10-28 | 2021-05-06 | Abraxis Bioscience, Llc | Pharmaceutical compositions of albumin and rapamycin |
| CN114945358A (zh) * | 2019-11-11 | 2022-08-26 | 阿布拉科斯生物科学有限公司 | 用于纳米颗粒组合物的生物标记 |
| KR102641217B1 (ko) * | 2019-12-24 | 2024-02-29 | (주)아이엠지티 | 항암제가 코팅된 알부민 나노입자 및 이의 제조방법 |
| KR102517033B1 (ko) | 2020-07-15 | 2023-04-03 | 성균관대학교산학협력단 | 엔도텔린 수용체 길항제를 봉입한 나노입자 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 |
| AU2021397776A1 (en) * | 2020-12-10 | 2023-06-22 | Children's Hospital Medical Center | Enhanced nanoparticle delivery systems |
| WO2022178218A1 (en) | 2021-02-19 | 2022-08-25 | Mevion Medical Systems, Inc. | Gantry for a particle therapy system |
| EP4326260A4 (en) * | 2021-04-20 | 2025-05-28 | The Regents of The University of Michigan | Pi3k inhibitors, nanoformulations, and uses thereof |
| KR102837034B1 (ko) | 2022-09-28 | 2025-07-22 | 충남대학교산학협력단 | 피로인산티아민 알부민 나노클러스터를 포함하는 항암치료용 조성물 및 이의 제조방법 |
| WO2024081674A1 (en) | 2022-10-11 | 2024-04-18 | Aadi Bioscience, Inc. | Combination therapies for the treatment of cancer |
| CN116271067A (zh) * | 2023-03-20 | 2023-06-23 | 山东大学齐鲁医院 | 一种基于hsp90抑制剂白蛋白纳米药物及其制备方法与应用 |
| WO2024228964A1 (en) | 2023-04-30 | 2024-11-07 | Aadi Bioscience, Inc. | Treatments comprising an mtor inhibitor nanoparticle composition |
| WO2024243413A1 (en) | 2023-05-24 | 2024-11-28 | Aadi Bioscience, Inc. | Combination therapy with a mtor inhibitor and a multi-tyrosine kinase inhibitor for treating soft tissue sarcoma |
| WO2025034870A1 (en) | 2023-08-08 | 2025-02-13 | Aadi Bioscience, Inc. | Combination of nab-sirolimus and an estrogen suppresor for use in the treatment of hormone-dependent cancers |
| WO2025049962A1 (en) | 2023-08-31 | 2025-03-06 | Aadi Bioscience, Inc. | Combination cancer treatments with a composition comprising an mtor pathway inhibitor |
| WO2025129108A1 (en) | 2023-12-14 | 2025-06-19 | Aadi Bioscience, Inc. | Methods of treating a cancer in an individual |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5206018A (en) * | 1978-11-03 | 1993-04-27 | Ayerst, Mckenna & Harrison, Inc. | Use of rapamycin in treatment of tumors |
| US5540931A (en) | 1989-03-03 | 1996-07-30 | Charles W. Hewitt | Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants |
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| US5665383A (en) | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of immunostimulating agents for in vivo delivery |
| US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| BR9405798A (pt) | 1993-02-22 | 1995-12-12 | Vivorx Pharmaceuticals Inc | Métodos para liberação in vivo de material biológico e composições úteis dos mesmos |
| US6528067B1 (en) | 1993-02-22 | 2003-03-04 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
| US20030068362A1 (en) | 1993-02-22 | 2003-04-10 | American Bioscience, Inc. | Methods and formulations for the delivery of pharmacologically active agents |
| US5665382A (en) | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of pharmaceutically active agents for in vivo delivery |
| US6753006B1 (en) | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
| US5650156A (en) | 1993-02-22 | 1997-07-22 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of nutriceuticals and compositions useful therefor |
| US5997904A (en) | 1993-02-22 | 1999-12-07 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
| US20070117862A1 (en) | 1993-02-22 | 2007-05-24 | Desai Neil P | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US5362478A (en) | 1993-03-26 | 1994-11-08 | Vivorx Pharmaceuticals, Inc. | Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell |
| US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| EP1683517A1 (en) | 1996-08-19 | 2006-07-26 | American Bioscience, Inc. | Methods for the production of protein particles useful for delivery of pharmacological agents |
| US20070092563A1 (en) | 1996-10-01 | 2007-04-26 | Abraxis Bioscience, Inc. | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| NZ502500A (en) | 1997-06-27 | 2002-03-28 | Vivorx Pharmaceuticals Inc | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US20030199425A1 (en) | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| EP1171117A4 (en) | 1999-04-22 | 2002-08-07 | American Bioscience Inc | LONG-TERM ADMINISTRATION OF PHARMACOLOGICALLY ACTIVE AGENTS |
| AU784416B2 (en) | 1999-05-21 | 2006-03-30 | Abraxis Bioscience, Llc | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| GB0008785D0 (en) * | 2000-04-10 | 2000-05-31 | Novartis Ag | Organic compounds |
| ITMI20001107A1 (it) | 2000-05-18 | 2001-11-18 | Acs Dobfar Spa | Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel |
| PL231418B1 (pl) * | 2001-02-19 | 2019-02-28 | Novartis Ag | 40-O-( 2-hydroksyetylo)- rapamycyna do zastosowania w leczeniu guzów litych płuc, innych niż nowotwór tkanki limfatycznej |
| MXPA03009092A (es) | 2001-04-06 | 2004-02-12 | Wyeth Corp | COMBINACIONES DE ANTINEOPLaSICOS COMO RAPAMICINA CON GEMCITABINA O FLUOROURACILO. |
| CN100496485C (zh) * | 2001-06-01 | 2009-06-10 | 惠氏公司 | 抗肿瘤组合 |
| US20030054042A1 (en) | 2001-09-14 | 2003-03-20 | Elaine Liversidge | Stabilization of chemical compounds using nanoparticulate formulations |
| JP4212921B2 (ja) * | 2002-03-29 | 2009-01-21 | 独立行政法人科学技術振興機構 | 抗体を提示するタンパク質中空ナノ粒子を用いる治療薬剤およびタンパク質中空ナノ粒子 |
| WO2003086178A2 (en) | 2002-04-11 | 2003-10-23 | Children's Medical Center Corporation | Methods for inhibiting vascular hyperpermeability |
| US20040126400A1 (en) * | 2002-05-03 | 2004-07-01 | Iversen Patrick L. | Delivery of therapeutic compounds via microparticles or microbubbles |
| SI1585548T1 (sl) | 2002-12-09 | 2018-11-30 | Abraxis Bioscience, Llc | Sestave in metode odmerjanja farmakoloških sredstev |
| KR20110079741A (ko) * | 2002-12-09 | 2011-07-07 | 아브락시스 바이오사이언스, 엘엘씨 | 약리학적 물질의 조성물 및 그 전달방법 |
| AU2003293529A1 (en) | 2002-12-16 | 2004-07-29 | Nitromed, Inc. | Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use |
| US20050119330A1 (en) | 2003-03-17 | 2005-06-02 | Kao Peter N. | Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases |
| US20050038498A1 (en) | 2003-04-17 | 2005-02-17 | Nanosys, Inc. | Medical device applications of nanostructured surfaces |
| US20050152979A1 (en) | 2003-09-05 | 2005-07-14 | Cell Therapeutics, Inc. | Hydrophobic drug compositions containing reconstitution enhancer |
| DE10347994A1 (de) | 2003-10-15 | 2005-06-16 | Pari GmbH Spezialisten für effektive Inhalation | Wässrige Aerosol-Zubereitung |
| ES2529660T3 (es) * | 2004-05-14 | 2015-02-24 | Abraxis Bioscience, Llc | Métodos de tratamiento en los que se utilizan las proteínas de unión a albúmina como dianas |
| WO2005110480A2 (en) | 2004-05-17 | 2005-11-24 | Novartis Ag | Combination of organic compounds |
| KR101506925B1 (ko) * | 2004-10-01 | 2015-03-30 | 램스코르 인코포레이티드 | 편리하게 이식가능한 서방형 약물 조성물 |
| WO2006053754A1 (en) | 2004-11-19 | 2006-05-26 | Novartis Ag | COMBINATIONS OF ANTI-ATHEROSCLEROTIC PEPTIDES AND AN mTOR INHIBITING AGENT AND THEIR METHODS OF USE |
| US20070166388A1 (en) | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| AU2006214001B2 (en) * | 2005-02-18 | 2011-05-26 | Samy Abdou | Devices and methods for dynamic fixation of skeletal structure |
| CN105879114A (zh) * | 2005-02-18 | 2016-08-24 | 阿布拉西斯生物科学公司 | 用于整合入医疗装置的疏水性改善的药物 |
| SI2301531T1 (sl) * | 2005-02-18 | 2018-11-30 | Abraxis Bioscience, Llc | Kombinacije in načini dajanja terapevtskih sredstev in kombinacijska terapija |
| CA2601312A1 (en) | 2005-03-17 | 2006-09-28 | Elan Pharma International Limited | Injectable compositions of nanoparticulate immunosuppressive compounds |
| DE102005016873A1 (de) * | 2005-04-12 | 2006-10-19 | Magforce Nanotechnologies Ag | Nanopartikel-Wirstoff-Konjugate |
| WO2006113579A2 (en) * | 2005-04-16 | 2006-10-26 | Michigan State University | Tumor inhibition by modulating sprouty expression or activity |
| BRPI0610818A2 (pt) | 2005-05-16 | 2010-07-27 | Novartis Ag | uso de derivados de rapamicina para o tratamento e/ou para a prevenção de distúrbios cardiovasculares |
| PL3311805T3 (pl) * | 2005-08-31 | 2020-07-27 | Abraxis Bioscience, Llc | Kompozycje zawierające słabo rozpuszczalne w wodzie środki farmaceutyczne i środki przeciwdrobnoustrojowe |
| CA2620389C (en) | 2005-08-31 | 2014-06-17 | Abraxis Bioscience, Llc | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
| US20070148251A1 (en) * | 2005-12-22 | 2007-06-28 | Hossainy Syed F A | Nanoparticle releasing medical devices |
| CA2662140A1 (en) | 2006-08-31 | 2008-03-06 | Abraxis Bioscience, Llc | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
| US20080280987A1 (en) | 2006-08-31 | 2008-11-13 | Desai Neil P | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
| US20100112077A1 (en) | 2006-11-06 | 2010-05-06 | Abraxis Bioscience, Llc | Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer |
| LT2117520T (lt) | 2006-12-14 | 2018-12-10 | Abraxis Bioscience, Llc | Krūties vėžio terapija hormonų receptoriaus statuso pagrindu su nanodalelėmis, apimančiomis taksaną |
| MX380318B (es) * | 2007-03-07 | 2025-03-12 | Abraxis Bioscience Llc | Nanoparticula que comprende rapamicina y albumina como agente anticancer. |
| US20100166869A1 (en) | 2007-05-03 | 2010-07-01 | Desai Neil P | Methods and compositions for treating pulmonary hypertension |
| AU2008260447B2 (en) | 2007-06-01 | 2013-10-10 | Abraxis Bioscience, Llc | Methods and compositions for treating recurrent cancer |
| CA2721153C (en) | 2008-04-10 | 2018-10-02 | Abraxis Bioscience, Llc | Compositions of hydrophobic taxane derivatives and uses thereof |
| NZ593343A (en) | 2008-12-11 | 2013-04-26 | Abraxis Bioscience Llc | Combination cancer treatment conprising Abraxane and an inflamatory inhibitor |
| KR101739598B1 (ko) | 2009-03-13 | 2017-06-08 | 아브락시스 바이오사이언스, 엘엘씨 | 티오콜키신 유도체와의 조합 요법 |
| AU2010233097B2 (en) | 2009-04-10 | 2016-04-07 | Abraxis Bioscience, Llc | Nanoparticle formulations and uses thereof |
| KR20120044279A (ko) | 2009-04-15 | 2012-05-07 | 아브락시스 바이오사이언스, 엘엘씨 | 무-프리온 나노입자 조성물 및 방법 |
| SG10201609290PA (en) | 2009-08-25 | 2016-12-29 | Abraxis Bioscience Llc | Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors |
| US9775819B2 (en) | 2009-09-16 | 2017-10-03 | R.P. Scherer Technologies, Llc | Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin |
| BR112012024349A2 (pt) | 2010-03-26 | 2016-05-24 | Abraxis Bioscience Llc | métodos de tratamento de carcinoma hepatocelular |
| CN105147613A (zh) | 2010-03-29 | 2015-12-16 | 阿布拉科斯生物科学有限公司 | 增强药物递送和治疗剂有效性的方法 |
| RU2016119999A (ru) | 2010-03-29 | 2018-11-08 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способы лечения онкологических заболеваний |
| EP2575803B1 (en) | 2010-06-02 | 2017-07-26 | Abraxis BioScience, LLC | Methods of treating bladder cancer |
| EP2575804A4 (en) * | 2010-06-04 | 2013-10-23 | Abraxis Bioscience Llc | METHOD FOR THE TREATMENT OF PANCREASCRE |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| CN105246468A (zh) * | 2013-03-14 | 2016-01-13 | 阿布拉科斯生物科学有限公司 | 治疗膀胱癌的方法 |
-
2008
- 2008-03-07 MX MX2015013895A patent/MX380318B/es unknown
- 2008-03-07 PL PL08726605T patent/PL2131821T3/pl unknown
- 2008-03-07 PT PT12152463T patent/PT2481409T/pt unknown
- 2008-03-07 SI SI200831982T patent/SI2481409T1/sl unknown
- 2008-03-07 PL PL12152463T patent/PL2481409T3/pl unknown
- 2008-03-07 CA CA3006137A patent/CA3006137C/en active Active
- 2008-03-07 LT LTEP12152463.1T patent/LT2481409T/lt unknown
- 2008-03-07 PT PT08726605T patent/PT2131821T/pt unknown
- 2008-03-07 LT LTEP08726605.2T patent/LT2131821T/lt unknown
- 2008-03-07 DK DK12152455.7T patent/DK2481402T3/en active
- 2008-03-07 HU HUE08726605A patent/HUE038701T2/hu unknown
- 2008-03-07 NZ NZ621972A patent/NZ621972A/en unknown
- 2008-03-07 SI SI200831985T patent/SI2481402T1/sl unknown
- 2008-03-07 EP EP12152463.1A patent/EP2481409B1/en active Active
- 2008-03-07 PT PT12152455T patent/PT2481402T/pt unknown
- 2008-03-07 BR BRPI0808635-4A patent/BRPI0808635B1/pt active IP Right Grant
- 2008-03-07 UA UAA201213559A patent/UA118645C2/uk unknown
- 2008-03-07 CN CN201510163181.4A patent/CN104814930B/zh active Active
- 2008-03-07 WO PCT/US2008/003096 patent/WO2008109163A1/en not_active Ceased
- 2008-03-07 HU HUE12152455A patent/HUE039643T2/hu unknown
- 2008-03-07 HU HUE12152463A patent/HUE039497T2/hu unknown
- 2008-03-07 PL PL12152455T patent/PL2481402T3/pl unknown
- 2008-03-07 EP EP12152455.7A patent/EP2481402B1/en active Active
- 2008-03-07 ES ES12152463.1T patent/ES2690175T3/es active Active
- 2008-03-07 ES ES08726605.2T patent/ES2686150T3/es active Active
- 2008-03-07 MX MX2009009537A patent/MX2009009537A/es active IP Right Grant
- 2008-03-07 EP EP18167003.5A patent/EP3417859A1/en active Pending
- 2008-03-07 HR HRP20181159TT patent/HRP20181159T1/hr unknown
- 2008-03-07 KR KR1020097020819A patent/KR20090118999A/ko not_active Ceased
- 2008-03-07 CA CA2680207A patent/CA2680207C/en active Active
- 2008-03-07 DK DK12152463.1T patent/DK2481409T3/en active
- 2008-03-07 RU RU2009136992/15A patent/RU2483714C2/ru active
- 2008-03-07 EP EP08726605.2A patent/EP2131821B1/en active Active
- 2008-03-07 CA CA3201293A patent/CA3201293A1/en active Pending
- 2008-03-07 DK DK08726605.2T patent/DK2131821T3/en active
- 2008-03-07 KR KR1020197001911A patent/KR102047634B1/ko active Active
- 2008-03-07 US US12/530,188 patent/US8911786B2/en active Active
- 2008-03-07 KR KR1020147033327A patent/KR20150002886A/ko not_active Ceased
- 2008-03-07 NZ NZ711695A patent/NZ711695A/en unknown
- 2008-03-07 JP JP2009552757A patent/JP2010520289A/ja not_active Withdrawn
- 2008-03-07 ES ES12152455.7T patent/ES2690174T3/es active Active
- 2008-03-07 LT LTEP12152455.7T patent/LT2481402T/lt unknown
- 2008-03-07 SI SI200831980T patent/SI2131821T1/sl unknown
- 2008-03-07 AU AU2008223334A patent/AU2008223334B2/en active Active
- 2008-03-07 KR KR1020197033753A patent/KR102154459B1/ko active Active
- 2008-03-07 KR KR1020177002049A patent/KR101943230B1/ko active Active
-
2009
- 2009-09-06 IL IL200755A patent/IL200755A/en active IP Right Grant
- 2009-09-11 ZA ZA2009/06342A patent/ZA200906342B/en unknown
-
2013
- 2013-02-27 US US13/779,621 patent/US20130280336A1/en not_active Abandoned
- 2013-03-04 RU RU2013109422A patent/RU2678448C2/ru active
- 2013-10-28 JP JP2013223132A patent/JP6348698B2/ja active Active
-
2014
- 2014-10-28 US US14/526,358 patent/US20150050356A1/en not_active Abandoned
-
2015
- 2015-10-14 JP JP2015202611A patent/JP2016011309A/ja not_active Withdrawn
-
2017
- 2017-02-05 IL IL250445A patent/IL250445A0/en unknown
- 2017-05-10 JP JP2017093894A patent/JP6544812B2/ja active Active
-
2018
- 2018-07-04 JP JP2018127659A patent/JP2018150381A/ja active Pending
- 2018-07-27 HR HRP20181198TT patent/HRP20181198T1/hr unknown
- 2018-07-30 HR HRP20181217TT patent/HRP20181217T1/hr unknown
- 2018-08-08 CY CY20181100826T patent/CY1120555T1/el unknown
- 2018-08-08 CY CY20181100824T patent/CY1120547T1/el unknown
- 2018-08-08 CY CY20181100825T patent/CY1120548T1/el unknown
- 2018-09-24 US US16/140,339 patent/US20190022020A1/en not_active Abandoned
-
2019
- 2019-01-22 RU RU2019101632A patent/RU2019101632A/ru not_active Application Discontinuation
- 2019-10-09 JP JP2019185794A patent/JP2020002177A/ja active Pending
-
2021
- 2021-02-24 US US17/184,506 patent/US20210322335A1/en not_active Abandoned
-
2023
- 2023-06-12 US US18/208,775 patent/US20240065984A1/en not_active Abandoned
-
2024
- 2024-11-19 US US18/952,634 patent/US20250186359A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20181217T1 (hr) | Nanočestica koja kao antikancerogeno sredstvo sadrži rapamicin i albumin | |
| IL208591A0 (en) | Nanoparticle formulations and uses thereof | |
| IL212339A (en) | Pyrolobenzodiazepine derivatives and processes for their preparation | |
| GB0913442D0 (en) | Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof | |
| IL215665A0 (en) | Nanoparticle formulations and uses therof | |
| IL211042A0 (en) | Imidazopyridin-2-one derivatives and uses thereof | |
| EP2084279A4 (en) | DNA-CONTROLLED NANOPARTICLE STRUCTURES | |
| IL194751A0 (en) | Drugs and uses | |
| PL2203523T3 (pl) | Nanocząstki typu rdzeń-powłoka | |
| GB2461473B (en) | Nanoparticles and fabrication thereof | |
| EP2253323A4 (en) | ANTIALLERGENIC ACTIVE SUBSTANCE | |
| IL199991A0 (en) | Soluble fcgammaria and related methods | |
| EP2213679A4 (en) | WATER SOLUBLE TRITERPENEPHENOL COMPOUNDS HAVING ANTI-TUMOR ACTIVITY AND PREPARATION THEREOF | |
| EP2236145A4 (en) | PHARMACEUTICAL COMPOSITION AND ACTIVE INGREDIENT COMBINATION | |
| AP2734A (en) | Pharmaceutical carrier composition and pharmaceutical composition | |
| GB2442951B (en) | Anticancer and antibacterial agents | |
| GB0609588D0 (en) | Nanoparticle Pharmaceutical Carrier | |
| IL217832A0 (en) | Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof | |
| GB0721438D0 (en) | Chemically modified chitosan as efficient anticancer agent | |
| GB0713426D0 (en) | Improvements in anticancer drugs | |
| AP2007004032A0 (en) | Pharmaceutical carrier composition and pharmaceutical composition |